Effect of cyclic AMP on barrier function of human lymphatic microvascular tubes

Microvasc Res. 2008 May;76(1):46-51. doi: 10.1016/j.mvr.2008.02.003. Epub 2008 Mar 18.

Abstract

This work examines the effect of cyclic AMP (cAMP) on the in vitro barrier function of tubes of human dermal lymphatic microvascular endothelial cells (LECs). Under baseline conditions, the barrier function of LEC tubes was weak, with diffusional permeability coefficients to bovine serum albumin and 10 kDa dextran of 1.4(-0.6)(+0.9)x10(-6) cm/s and 1.7(-0.5)(+0.8)x10(-6) cm/s (geometric mean+/-95% CI), respectively, and 1.2+/-0.5 (mean+/-95% CI) focal leaks per mm. Exposure to low concentrations (3 microM) of a cell-permeant analog of cAMP did not alter the barrier function. Exposure to higher concentrations (80 and 400 microM) and/or the phosphodiesterase inhibitor Ro-20-1724 (20 microM) lowered permeabilities and the number of focal leaks, and increased the selectivity of the barrier. Decreased permeabilities were accompanied by an increase in continuous VE-cadherin staining at cell-cell borders. Exposure to 1 mM 2',5'-dideoxyadenosine, an inhibitor of adenylate cyclase, did not increase permeabilities. LECs expressed the lymphatic-specific master transcription factor Prox-1, regardless of whether barrier function was weak or strong. Our results indicate that the permeability of LEC tubes in vitro responds to cAMP in a manner similar to that well-described for the permeability of blood microvessels.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / pharmacology
  • Adenylyl Cyclase Inhibitors
  • Adherens Junctions / drug effects
  • Adherens Junctions / metabolism
  • Antigens, CD / metabolism
  • Bucladesine / pharmacology
  • Cadherins / metabolism
  • Capillary Permeability / drug effects*
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Cells, Cultured
  • Cyclic AMP / analogs & derivatives
  • Cyclic AMP / pharmacology*
  • Dextrans / metabolism
  • Dideoxyadenosine / analogs & derivatives
  • Dideoxyadenosine / pharmacology
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Endothelium, Lymphatic / cytology
  • Endothelium, Lymphatic / drug effects*
  • Endothelium, Lymphatic / metabolism
  • Enzyme Inhibitors / pharmacology
  • Homeodomain Proteins / metabolism
  • Humans
  • Membrane Glycoproteins / metabolism
  • Membrane Proteins / metabolism
  • Phosphoproteins / metabolism
  • Platelet Endothelial Cell Adhesion Molecule-1 / metabolism
  • Serum Albumin, Bovine / metabolism
  • Tight Junctions / drug effects
  • Tight Junctions / metabolism
  • Tissue Engineering / methods
  • Tumor Suppressor Proteins / metabolism
  • Zonula Occludens-1 Protein

Substances

  • Adenylyl Cyclase Inhibitors
  • Antigens, CD
  • Cadherins
  • Dextrans
  • Enzyme Inhibitors
  • Homeodomain Proteins
  • Membrane Glycoproteins
  • Membrane Proteins
  • PDPN protein, human
  • Phosphoproteins
  • Platelet Endothelial Cell Adhesion Molecule-1
  • TJP1 protein, human
  • Tumor Suppressor Proteins
  • Zonula Occludens-1 Protein
  • cadherin 5
  • prospero-related homeobox 1 protein
  • Serum Albumin, Bovine
  • 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
  • Dideoxyadenosine
  • Bucladesine
  • 2',5'-dideoxyadenosine
  • Cyclic AMP